Aeglea Biotherapeutics Inc. (AGLE) Upgraded by Zacks Investment Research to Hold
Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “
Shares of Aeglea Biotherapeutics (NASDAQ:AGLE) traded up 6.15% during trading on Tuesday, reaching $6.90. 9,785 shares of the company’s stock were exchanged. The stock has a 50 day moving average price of $6.67 and a 200-day moving average price of $6.59. The stock’s market capitalization is $92.54 million. Aeglea Biotherapeutics has a 52 week low of $3.89 and a 52 week high of $12.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/aeglea-biotherapeutics-inc-agle-upgraded-by-zacks-investment-research-to-hold.html
Aeglea Biotherapeutics (NASDAQ:AGLE) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.03. Analysts predict that Aeglea Biotherapeutics will post ($4.77) earnings per share for the current year.
Institutional investors have recently made changes to their positions in the company. VHCP Management II LLC bought a new position in Aeglea Biotherapeutics during the second quarter worth $1,527,000. Ghost Tree Capital LLC bought a new position in Aeglea Biotherapeutics during the second quarter worth $243,000. Finally, Perceptive Advisors LLC bought a new position in Aeglea Biotherapeutics during the second quarter worth $515,000. Institutional investors own 40.71% of the company’s stock.
About Aeglea Biotherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.